Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PMV Pharmaceuticals, Inc. (PMVP)
USD1.39
-0.03 (-2.11%)
US NASDAQ Healthcare Biotechnology
Address
8 Clarke Drive 8512
Princeton, NJ, US
Princeton, NJ, US
CEO
David H. Mack
Website
pmvpharma.com
IPO
2020-09-25
CIK 1699382 ISIN US69353Y1038
Description
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.39
-0.03 (-2.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
370.7K
Beta
1.36
Float Shares
48.89M
Free Float %
91.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.16% | -0.70% | +7.58% | +31.48% | +0.00% | +13.60% | +64.35% | -75.09% | -94.99% | -96.21% | -96.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.39
Low
5.00
+259.7%
Consensus
18.00
+1,195.0%
Median
15.50
+1,015.1%
High
36.00
+2,489.9%
DCF (Unlevered)
0.65
-53.0%
DCF (Levered)
0.71
-49.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 5 |
21.00
+1,410.8%
|
Quality scores
Altman Z-Score
-3.23
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-30.0% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.9% ★ Q1'26: +2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 30.0K (-100.0%)
|
—
|
—
|
2.93M
2.93M – 2.93M
|
2.96M
2.96M – 2.96M
+1.3% YoY
|
24.30M
24.30M – 24.30M
+719.9% YoY
|
55.81M
55.81M – 55.81M
+129.6% YoY
|
155.36M
155.36M – 155.36M
+178.4% YoY
|
| EBITDA |
-34.12M
|
-73.67M
|
-86.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-34.43M
|
-74.81M
|
-86.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-34.44M
est: -106.12M (+67.5%)
|
-58.71M
est: -65.25M (+10.0%)
|
-77.74M
est: -79.86M (+2.7%)
|
-82.49M
-85.62M – -79.36M
-3.3% YoY
|
-60.69M
-63.55M – -57.82M
+26.4% YoY
|
-43.35M
-43.35M – -43.35M
+28.6% YoY
|
-30.47M
-30.47M – -30.47M
+29.7% YoY
|
8.93M
8.93M – 8.93M
+129.3% YoY
|
| SGA |
11.01M
|
26.92M
|
16.33M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.40
est: -2.06 (-16.6%)
|
-1.14
est: -1.27 (+10.0%)
|
-1.48
est: -1.52 (+2.3%)
|
-1.57
-1.63 – -1.51
-3.6% YoY
|
-1.16
-1.21 – -1.10
+26.1% YoY
|
-0.83
-0.83 – -0.83
+28.9% YoY
|
-0.58
-0.58 – -0.58
+29.7% YoY
|
0.17
0.17 – 0.17
+129.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
7.74M
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 5.17M | 11.00% | — | 5.14M | — | 5.17M | HC | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 2 | SSGA FUNDS MANAGEMENT, INC. | 4.66M | 10.23% | — | 4.66M | — | 4.66M | IA | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 3 | JPMORGAN CHASE & CO.13-2624428 | 4.59M | 10.00% | 3.70M | — | 4.58M | — | HC | Delaware | 2022-07-07 | ↗ |
| 4 | BML Investment Partners, L.P. | 3.27M | 6.30% | — | 3.27M | — | 3.27M | PN | Delaware | 2024-12-12 | ↗ |
| 5 | Khaled A. Nasr (a Venture Member of InterWest Management Partners X, LLC) | 3.25M | 7.20% | 14.6K | 3.23M | 14.6K | 3.23M | IN | — | 2022-02-14 | ↗ |
| 6 | Keval Desai (a Venture Member of InterWest Management Partners X, LLC) | 3.24M | 7.10% | 9.8K | 3.23M | 9.8K | 3.23M | IN | — | 2022-02-14 | ↗ |
| 7 | Gilbert H. Kliman (a Managing Director of InterWest Management Partners X, LLC) | 3.24M | 7.10% | 5.0K | 3.23M | 5.0K | 3.23M | IN | — | 2022-02-14 | ↗ |
| 8 | InterWest Management Partners X, LLC (the General Partner of InterWest Partners X, LP) | 3.23M | 7.10% | 3.23M | — | 3.23M | — | OO | — | 2022-02-14 | ↗ |
| 9 | InterWest Partners X, LP (“IWP X”) | 3.23M | 7.10% | 3.23M | — | 3.23M | — | PN | — | 2022-02-14 | ↗ |
| 10 | RTW Investments, LP | 2.98M | 6.60% | — | 2.98M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 11 | Roderick Wong | 2.98M | 6.60% | — | 2.98M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 12 | Boxer Asset Management Inc. | 2.84M | 6.30% | — | 2.84M | — | 2.84M | CO | — | 2022-02-14 | ↗ |
| 13 | Boxer Capital, LLC | 2.84M | 6.30% | — | 2.84M | — | 2.84M | OO | — | 2022-02-14 | ↗ |
| 14 | Joe Lewis | 2.84M | 6.30% | — | 2.84M | — | 2.84M | IN | — | 2022-02-14 | ↗ |
| 15 | ArrowMark Colorado Holdings, LLC | 2.71M | 5.31% | 2.71M | — | 2.71M | — | IA | Delaware, United States | 2024-02-14 | ↗ |
| 16 | The Vanguard Group - 23-1945930 | 2.65M | 5.84% | — | 48.1K | — | 61.7K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 17 | (1) BlackRock, Inc. | 2.54M | 5.60% | 2.52M | — | 2.54M | — | HC | Delaware | 2022-02-04 | ↗ |
| 18 | Ashvin B. Chhabra | 2.34M | 5.10% | — | 2.34M | — | 2.34M | IN | — | 2022-02-14 | ↗ |
| 19 | Euclidean Capital LLC | 2.34M | 5.10% | — | 2.34M | — | 2.34M | OO | — | 2022-02-14 | ↗ |
| 20 | James H. Simons | 2.34M | 5.10% | — | 2.34M | — | 2.34M | IN | — | 2022-02-14 | ↗ |
| 21 | Marilyn H. Simons | 2.34M | 5.10% | — | 2.34M | — | 2.34M | IN | — | 2022-02-14 | ↗ |
| 22 | David C. Ott | 1.79M | 3.90% | — | 1.79M | — | 1.79M | IN | Delaware | 2022-02-14 | ↗ |
| 23 | O. Andreas Halvorsen | 1.79M | 3.90% | — | 1.79M | — | 1.79M | IN | Delaware | 2022-02-14 | ↗ |
| 24 | Rose S. Shabet | 1.79M | 3.90% | — | 1.79M | — | 1.79M | IN | Delaware | 2022-02-14 | ↗ |
| 25 | Viking Global Investors LP | 1.79M | 3.90% | — | 1.79M | — | 1.79M | PN | Delaware | 2022-02-14 | ↗ |
| 26 | Viking Global Opportunities GP LLC | 1.79M | 3.90% | — | 1.79M | — | 1.79M | OO | Delaware | 2022-02-14 | ↗ |
| 27 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.79M | 3.90% | — | 1.79M | — | 1.79M | PN | Delaware | 2022-02-14 | ↗ |
| 28 | Viking Global Opportunities Parent GP LLC | 1.79M | 3.90% | — | 1.79M | — | 1.79M | OO | Delaware | 2022-02-14 | ↗ |
| 29 | Viking Global Opportunities Portfolio GP LLC | 1.79M | 3.90% | — | 1.79M | — | 1.79M | OO | Delaware | 2022-02-14 | ↗ |
| 30 | Greenland NFP B Ltd. | 1.30M | 2.90% | — | 1.30M | — | 1.30M | OO | — | 2022-02-14 | ↗ |
| 31 | Greenland FP LLC | 375.7K | 0.80% | — | 375.7K | — | 375.7K | OO | — | 2022-02-14 | ↗ |
| 32 | Greenland A LLC | 346.9K | 0.80% | — | 346.9K | — | 346.9K | OO | — | 2022-02-14 | ↗ |
| 33 | Symmetry Group Ltd. | 247.2K | 0.50% | — | 247.2K | — | 247.2K | OO | — | 2022-02-14 | ↗ |
| 34 | Greenland NFP LLC | 66.3K | 0.10% | — | 66.3K | — | 66.3K | OO | — | 2022-02-14 | ↗ |
| 35 | Aaron I. Davis | 60.8K | 0.10% | — | 60.8K | — | 60.8K | IN | — | 2022-02-14 | ↗ |
| 36 | MVA Investors, LLC | 60.8K | 0.10% | — | 60.8K | — | 60.8K | CO | — | 2022-02-14 | ↗ |
| 37 | 2. | 10.00 | 4.90% | — | 2.26M | — | — | HC, IN | Delaware | 2023-05-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-57 vs prev Q
New positions
1
Closed positions
57
Increased
3
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BML CAPITAL MANAGEMENT, LLC | 5.29M +— (+0.0%) | 6.62M -793.8K (-10.7%) | 9.99% -0.189 pp | 5.72% -1.066 pp | USD1.44 -13.2% | 8 qtrs — |
| 2 | ORBIMED ADVISORS LLC | 4.98M -1.0M (-16.7%) | 6.22M -2.1M (-25.7%) | 9.39% -2.100 pp | 0.13% -0.070 pp | USD35.50 -96.5% | 22 qtrs — |
| 3 | TANG CAPITAL MANAGEMENT LLC | 4.94M +154.8K (+3.2%) | 6.18M -524.3K (-7.8%) | 9.32% +0.122 pp | 0.31% +0.047 pp | USD1.40 -10.7% | 2 qtrs — |
| 4 | ARROWMARK COLORADO HOLDINGS LLC | 3.09M -211.2K (-6.4%) | 3.86M -759.3K (-16.4%) | 5.83% -0.516 pp | 0.09% -0.001 pp | USD3.91 -68.0% | 22 qtrs — |
| 5 | SIO CAPITAL MANAGEMENT, LLC | 2.64M +— (+0.0%) | 3.30M -395.5K (-10.7%) | 4.98% -0.094 pp | 0.52% -0.416 pp | USD1.54 -18.8% | 7 qtrs — |
| 6 | EUCLIDEAN CAPITAL LLC | 2.63M +— (+0.0%) | 3.28M -394.1K (-10.7%) | 4.96% -0.094 pp | 0.89% -0.657 pp | USD55.39 -97.7% | 21 qtrs — |
| 7 | VANGUARD GROUP INC | 2.17M +7.3K (+0.3%) | 2.71M -315.4K (-10.4%) | 4.10% -0.063 pp | 0.00% +0.000 pp | USD30.65 -95.9% | 22 qtrs — |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 2.02M -50.4K (-2.4%) | 2.52M -373.0K (-12.9%) | 3.80% -0.169 pp | 0.00% -0.001 pp | USD2.26 -44.7% | 9 qtrs — |
| 9 | STONEPINE CAPITAL MANAGEMENT, LLC | 1.15M -219.4K (-16.0%) | 1.44M -479.7K (-25.0%) | 2.17% -0.463 pp | 1.05% -0.509 pp | USD1.37 -8.8% | 5 qtrs — |
| 10 | BLACKROCK, INC. | 1.09M -9.3K (-0.8%) | 1.37M -177.2K (-11.5%) | 2.07% -0.057 pp | 0.00% +0.000 pp | USD1.49 -16.1% | 6 qtrs — |
| 11 | TWO SIGMA ADVISERS, LP | 874.1K +456.2K (+109.2%) | 1.09M +507.6K (+86.8%) | 1.65% +0.846 pp | 0.00% +0.001 pp | USD1.66 -24.7% | 12 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 706.1K +436.4K (+161.9%) | 882.6K +505.1K (+133.8%) | 1.33% +0.814 pp | 0.00% +0.001 pp | USD1.76 -29.0% | 18 qtrs — |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 524.4K +455.7K (+663.6%) | 655.4K +559.3K (+581.8%) | 0.99% +0.857 pp | 0.00% +0.002 pp | USD1.27 -1.6% | 9 qtrs — |
| 14 | JANE STREET GROUP, LLC | 498.6K +116.6K (+30.5%) | 623.3K +88.4K (+16.5%) | 0.94% +0.206 pp | 0.00% +0.000 pp | USD1.36 -8.1% | 2 qtrs — |
| 15 | ALDEBARAN CAPITAL, LLC | 478.0K -26.1K (-5.2%) | 597.5K -108.3K (-15.3%) | 0.90% -0.067 pp | 0.54% -0.113 pp | USD1.54 -18.8% | 7 qtrs — |
| 16 | MARSHALL WACE, LLP | 465.1K -147.5K (-24.1%) | 581.4K -276.3K (-32.2%) | 0.88% -0.300 pp | 0.00% 0.000 pp | USD1.40 -10.7% | 2 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 446.1K +14.3K (+3.3%) | 557.8K -46.9K (-7.8%) | 0.84% +0.012 pp | 0.00% +0.000 pp | USD25.28 -95.1% | 22 qtrs — |
| 18 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 428.9K +108.2K (+33.7%) | 536.1K +87.2K (+19.4%) | 0.81% +0.193 pp | 0.01% +0.002 pp | USD1.81 -30.9% | 11 qtrs — |
| 19 | NORTHERN TRUST CORP | 382.1K +1.3K (+0.3%) | 477.6K -55.5K (-10.4%) | 0.72% -0.011 pp | 0.00% +0.000 pp | USD9.39 -86.7% | 22 qtrs — |
| 20 | WALLEYE CAPITAL LLC | 335.7K +57.2K (+20.6%) | 419.6K +29.8K (+7.6%) | 0.63% +0.098 pp | 0.00% 0.000 pp | USD1.54 -18.8% | 12 qtrs — |
| 21 | BANK OF AMERICA CORP /DE/ | 240.1K +77.6K (+47.8%) | 300.2K +72.7K (+31.9%) | 0.45% +0.141 pp | 0.00% +0.000 pp | USD1.69 -26.0% | 22 qtrs — |
| 22 | STATE STREET CORP | 183.2K +25.6K (+16.2%) | 229.0K +8.4K (+3.8%) | 0.35% +0.043 pp | 0.00% +0.000 pp | USD15.04 -91.7% | 21 qtrs — |
| 23 | RBF CAPITAL, LLC | 162.2K -83.4K (-33.9%) | 202.8K -141.0K (-41.0%) | 0.31% -0.166 pp | 0.01% -0.006 pp | USD1.58 -20.9% | 7 qtrs — |
| 24 | ASSENAGON ASSET MANAGEMENT S.A. | 140.5K +17.4K (+14.1%) | 175.6K +3.3K (+1.9%) | 0.27% +0.028 pp | 0.00% +0.000 pp | USD2.85 -56.1% | 19 qtrs — |
| 25 | EVOKE WEALTH, LLC | 133.1K +— (+0.0%) | 166.4K -20.0K (-10.7%) | 0.25% -0.005 pp | 0.00% -0.001 pp | USD1.53 -18.3% | 7 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 127.0K -43.8K (-25.6%) | 158.8K -80.3K (-33.6%) | 0.24% -0.089 pp | 0.00% +0.000 pp | USD7.20 -82.6% | 22 qtrs — |
| 27 | CITADEL ADVISORS LLC | 118.6K -74.6K (-38.6%) | 148.2K -122.2K (-45.2%) | 0.22% -0.148 pp | 0.00% +0.000 pp | USD1.43 -12.6% | 22 qtrs — |
| 28 | XTX TOPCO LTD | 104.5K +61.7K (+144.3%) | 130.6K +70.7K (+118.2%) | 0.20% +0.115 pp | 0.00% +0.000 pp | USD1.31 -4.6% | 2 qtrs — |
| 29 | ADAR1 CAPITAL MANAGEMENT, LLC | 101.0K +— (+0.0%) | 126.3K -15.2K (-10.7%) | 0.19% -0.004 pp | 0.01% -0.004 pp | USD1.55 -19.4% | 8 qtrs — |
| 30 | MORGAN STANLEY | 98.9K +66.5K (+205.2%) | 123.6K +78.2K (+172.5%) | 0.19% +0.124 pp | 0.00% +0.000 pp | USD4.43 -71.8% | 22 qtrs — |
| 31 | IKARIAN CAPITAL, LLC | 89.1K -8.4K (-8.6%) | 111.4K -25.1K (-18.4%) | 0.17% -0.019 pp | 0.01% -0.005 pp | USD1.40 -10.7% | 2 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 78.8K +53.2K (+207.3%) | 98.5K +62.6K (+174.4%) | 0.15% +0.099 pp | 0.00% +0.000 pp | USD1.19 +5.0% | 3 qtrs — |
| 33 | PNC FINANCIAL SERVICES GROUP, INC. | 73.2K +2.2K (+3.1%) | 91.5K -7.9K (-7.9%) | 0.14% +0.002 pp | 0.00% +0.000 pp | USD1.52 -17.8% | 12 qtrs — |
| 34 | AMERIPRISE FINANCIAL INC | 65.1K +54.2K (+495.2%) | 81.4K +66.1K (+431.4%) | 0.12% +0.102 pp | 0.00% +0.000 pp | USD1.28 -2.3% | 21 qtrs — |
| 35 | — | 63.5K +63.5K (+100.0%) | 79.4K +79.4K (+100.0%) | 0.12% +0.120 pp | 0.06% +0.060 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 36 | ALGERT GLOBAL LLC | 62.0K +— (+0.0%) | 78.0K -9.0K (-10.3%) | 0.12% -0.002 pp | 0.00% 0.000 pp | USD1.40 -10.7% | 2 qtrs — |
| 37 | RANGELEY CAPITAL, LLC | 45.5K +— (+0.0%) | 56.9K -6.8K (-10.7%) | 0.09% -0.002 pp | 0.05% -0.008 pp | USD1.40 -10.7% | 2 qtrs — |
| 38 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 35.0K +— (+0.0%) | 43.8K -5.3K (-10.7%) | 0.07% -0.001 pp | 0.03% -0.021 pp | USD1.51 -17.2% | 5 qtrs — |
| 39 | HSBC HOLDINGS PLC | 30.9K +— (+0.0%) | 39.4K -3.7K (-8.6%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD4.43 -71.8% | 12 qtrs — |
| 40 | POINT72 ASSET MANAGEMENT, L.P. | 28.7K +28.7K (+100.0%) | 35.9K +35.9K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 41 | SIMPLEX TRADING, LLC | 27.9K +7.1K (+34.3%) | 34.8K +5.8K (+20.1%) | 0.05% +0.013 pp | 0.00% +0.000 pp | USD1.36 -8.1% | 2 qtrs — |
| 42 | BARCLAYS PLC | 27.5K -2.7K (-9.0%) | 34.4K -10.7K (-23.6%) | 0.05% -0.006 pp | 0.00% +0.000 pp | USD7.85 -84.1% | 16 qtrs — |
| 43 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 27.4K +21.3K (+349.7%) | 34.3K +25.8K (+301.6%) | 0.05% +0.040 pp | 0.00% +0.000 pp | USD1.28 -2.3% | 9 qtrs — |
| 44 | BOOTHBAY FUND MANAGEMENT, LLC | 27.1K -174.4K (-86.5%) | 33.9K -248.2K (-88.0%) | 0.05% -0.336 pp | 0.00% -0.004 pp | USD1.40 -10.7% | 2 qtrs — |
| 45 | SQUAREPOINT OPS LLC | 26.5K +13.4K (+101.8%) | 33.1K +14.7K (+80.2%) | 0.05% +0.025 pp | 0.00% +0.000 pp | USD1.40 -10.7% | 7 qtrs — |
| 46 | TWO SIGMA SECURITIES, LLC | 23.4K +23.4K (+100.0%) | 29.2K +29.2K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.004 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 47 | CITIGROUP INC | 19.3K -1.0 (0.0%) | 24.1K -2.9K (-10.7%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD6.21 -79.9% | 21 qtrs — |
| 48 | QUADRATURE CAPITAL LTD | 18.4K +18.4K (+100.0%) | 23.0K +23.0K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 49 | PATHSTONE HOLDINGS, LLC | 17.5K +— (+0.0%) | 21.9K -2.6K (-10.7%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.06 +17.9% | 3 qtrs — |
| 50 | BAILARD, INC. | 17.1K +17.1K (+100.0%) | 21.3K +21.3K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.001 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 51 | NINE MASTS CAPITAL LTD | 16.6K +16.6K (+100.0%) | 20.8K +20.8K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.004 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 52 | VIRTU FINANCIAL LLC | 12.8K +12.8K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD1.25 +0.0% | 1 qtrs NEW |
| 53 | INDEPENDENT ADVISOR ALLIANCE | 12.5K +— (+0.0%) | 15.6K -1.9K (-10.7%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD3.01 -58.5% | 9 qtrs — |
| 54 | GTS SECURITIES LLC | 10.0K +1.0 (+0.0%) | 12.5K -1.5K (-10.7%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD1.40 -10.7% | 2 qtrs — |
| 55 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 8.8K +— (+0.0%) | 11.0K -1.3K (-10.7%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.06 +17.9% | 3 qtrs — |
| 56 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.9K +3.9K (+100.0%) | 4.9K +4.9K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD1.25 +0.0% | 21 qtrs — |
| 57 | UBS GROUP AG | 1.1K -453.0 (-29.2%) | 1.4K -799.0 (-36.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.26 -70.7% | 22 qtrs — |
| 58 | JONES FINANCIAL COMPANIES LLLP | 1.0K -16.0 (-1.6%) | 1.3K -254.0 (-16.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.50 -16.7% | 5 qtrs — |
| 59 | BNP PARIBAS ARBITRAGE, SNC | 518.00 -27.0 (-5.0%) | 648.00 -115.0 (-15.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.51 -17.2% | 5 qtrs — |
| 60 | JPMORGAN CHASE & CO | 214.00 -700.0 (-76.6%) | 268.00 -1.0K (-79.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.06 -39.3% | 22 qtrs — |
| 61 | DIADEMA PARTNERS LP | — -11.3K (-100.0%) | — -15.8K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 62 | PEAPOD LANE CAPITAL LLC | — -202.8K (-100.0%) | — -283.9K (-100.0%) | 0.00% -0.390 pp | 0.00% -0.254 pp | USD— | 5 qtrs SOLD |
| 63 | PANAGORA ASSET MANAGEMENT INC | — -72.1K (-100.0%) | — -100.9K (-100.0%) | 0.00% -0.139 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 64 | DIMENSIONAL FUND ADVISORS LP | — -16.0K (-100.0%) | — -22.4K (-100.0%) | 0.00% -0.031 pp | 0.00% +0.000 pp | USD— | 15 qtrs SOLD |
| 65 | ROYAL BANK OF CANADA | — -4.1K (-100.0%) | — -6.0K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 66 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 67 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | — -20.0 (-100.0%) | — -28.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 68 | D. E. SHAW & CO., INC. | — -55.7K (-100.0%) | — -78.0K (-100.0%) | 0.00% -0.107 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 69 | FNY INVESTMENT ADVISERS, LLC | — -15.0K (-100.0%) | — -21.0K (-100.0%) | 0.00% -0.029 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 70 | PERSISTENT ASSET PARTNERS LTD | — -2.6K (-100.0%) | — -3.6K (-100.0%) | 0.00% -0.005 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 199.1K | 0.60% |
| 2 | Avantis Total Equity Markets ETF 1 AVTM | 0.00% | 5.9K | 0.23% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 530.6K | 0.05% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 766.97 | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.8K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 10.4K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.77M | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.9K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.1K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 855.07 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.18
Bearish
Buys
1
Sells
2
Shares acquired
220.6K
Shares disposed
1.22M
Cash buys
—
Cash sales
1.00
Net activity
-1,000,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Ticktin Robert | Officer | A-Award | A | Employee Stock Option (right to buy) | 319,270 | 1.53 | 488.5K | 319,270 | D | ↗ |
| 2026-03-05 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 744,960 | 1.53 | 1.14M | 744,960 | D | ↗ |
| 2026-03-05 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 303,310 | 1.53 | 464.1K | 303,310 | D | ↗ |
| 2026-03-05 | Carulli Michael | Officer | A-Award | A | Employee Stock Option (right to buy) | 240,000 | 1.53 | 367.2K | 240,000 | D | ↗ |
| 2025-10-27 | Mack David Henry | Director / Officer | M-Exempt | A | Common Stock | 220,643 | 1.37 | 302.3K | 451,109 | D | ↗ |
| 2025-10-23 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 1,000,000 | 1.52 | 1.52M | 4,975,291 | I | ↗ |
| 2025-09-10 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 500,000 | 1.80 | 900.0K | 5,975,291 | I | ↗ |
| 2025-07-01 | Ticktin Robert | Officer | S-Sale | D | Common Stock | 23,151 | 1.06 | 24.7K | 98,695 | D | ↗ |
| 2025-07-01 | Mack David Henry | Director / Officer | S-Sale | D | Common Stock | 58,411 | 1.06 | 62.2K | 536,133 | D | ↗ |
| 2025-07-01 | Jalota Deepika | Officer | S-Sale | D | Common Stock | 33,065 | 1.06 | 35.2K | 89,959 | D | ↗ |
| 2025-07-01 | Carulli Michael | Officer | S-Sale | D | Common Stock | 28,249 | 1.06 | 30.1K | 60,146 | D | ↗ |
| 2025-06-05 | Stelzer Laurie | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-06-05 | LEVINE ARNOLD J | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-06-05 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-06-05 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-06-05 | FLOWERS KIRSTEN | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-06-05 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 33,500 | 0.95 | 31.8K | 33,500 | D | ↗ |
| 2025-04-21 | Ticktin Robert | Officer | — | — | Common Stock | 0 | 0.00 | — | 106,318 | D | ↗ |
| 2025-03-03 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 800,000 | 1.32 | 1.06M | 800,000 | D | ↗ |
| 2025-03-03 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.32 | 396.0K | 300,000 | D | ↗ |
| 2025-03-03 | Carulli Michael | Officer | A-Award | A | Employee Stock Option (right to buy) | 265,000 | 1.32 | 349.8K | 265,000 | D | ↗ |
| 2025-01-03 | Mack David Henry | Director / Officer | M-Exempt | A | Common Stock | 17,709 | 0.53 | 9.4K | 551,919 | D | ↗ |
| 2024-12-03 | Mack David Henry | Director / Officer | M-Exempt | A | Common Stock | 91,750 | 0.53 | 48.6K | 534,210 | D | ↗ |
| 2024-09-11 | Jalota Deepika | Officer | S-Sale | D | Common Stock | 7,218 | 1.50 | 10.9K | 118,283 | — | ↗ |
| 2024-09-11 | Carulli Michael | Officer | S-Sale | D | Common Stock | 2,891 | 1.50 | 4.3K | 88,395 | — | ↗ |
| 2024-08-13 | Mack David Henry | Director / Officer | D-Return | D | Employee Stock Option (right to buy) | 134,584 | 28.33 | 3.81M | 0 | D | ↗ |
| 2024-08-13 | Jalota Deepika | Officer | D-Return | D | Employee Stock Option (right to buy) | 68,100 | 16.29 | 1.11M | 0 | D | ↗ |
| 2024-08-13 | Carulli Michael | Officer | D-Return | D | Employee Stock Option (right to buy) | 27,200 | 16.29 | 443.1K | 0 | D | ↗ |
| 2024-06-07 | Gallagher Carol Giltner | Director | G-Gift | D | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 0 | — | ↗ |
| 2024-06-06 | Stelzer Laurie | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-06-06 | LEVINE ARNOLD J | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-06-06 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-06-06 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-06-06 | FLOWERS KIRSTEN | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-06-06 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 67,500 | 1.65 | 111.4K | 67,500 | — | ↗ |
| 2024-01-18 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 519,915 | 1.80 | 935.8K | 519,915 | — | ↗ |
| 2024-01-18 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 225,095 | 1.80 | 405.2K | 225,095 | — | ↗ |
| 2024-01-18 | Carulli Michael | Officer | A-Award | A | Employee Stock Option (right to buy) | 204,630 | 1.80 | 368.3K | 204,630 | — | ↗ |
| 2024-01-05 | Carulli Michael | Officer | — | D | Employee Stock Option (right to buy) | 13,605 | 28.33 | 385.4K | 0 | — | ↗ |
| 2023-11-22 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 87,786 | 2.23 | 195.8K | 0 | — | ↗ |
| 2023-11-10 | Mack David Henry | Director / Officer | G-Gift | D | Common Stock | 85,307 | 0.00 | — | 278,570 | — | ↗ |
| 2023-10-18 | Mack David Henry | Director / Officer | M-Exempt | A | Common Stock | 198,407 | 0.53 | 105.2K | 363,877 | — | ↗ |
| 2023-09-15 | Jalota Deepika | Officer | S-Sale | D | Common Stock | 4,104 | 6.62 | 27.2K | 29,946 | — | ↗ |
| 2023-09-15 | Alland Leila | Officer | S-Sale | D | Common Stock | 6,291 | 6.62 | 41.6K | 45,909 | — | ↗ |
| 2023-08-07 | Mack David Henry | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 198,407 | 0.53 | 105.2K | 109,459 | — | ↗ |
| 2023-06-08 | Stelzer Laurie | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-06-08 | LEVINE ARNOLD J | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-06-08 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-06-08 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-06-08 | FLOWERS KIRSTEN | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-06-08 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 21,500 | 5.59 | 120.2K | 21,500 | — | ↗ |
| 2023-05-12 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 330,000 | 5.70 | 1.88M | 330,000 | — | ↗ |
| 2023-05-12 | Kung Winston | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 5.70 | 855.0K | 150,000 | — | ↗ |
| 2023-05-12 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 5.70 | 712.5K | 125,000 | — | ↗ |
| 2023-05-12 | Alland Leila | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 5.70 | 570.0K | 100,000 | — | ↗ |
| 2022-11-25 | Kung Winston | Officer | G-Gift | D | Common Stock | 2,560 | 0.00 | — | 10,600 | — | ↗ |
| 2022-11-05 | Gallagher Carol Giltner | Director | G-Gift | A | Stock Option (right to buy) | 39,000 | 0.00 | — | 39,000 | — | ↗ |
| 2022-11-04 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 39,000 | 0.00 | — | 39,000 | — | ↗ |
| 2022-11-03 | Gallagher Carol Giltner | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-06-02 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 16,333 | 32.29 | 527.4K | 16,333 | — | ↗ |
| 2022-06-02 | Stelzer Laurie | Director | A-Award | D | Stock Option | 19,500 | 13.56 | 264.4K | 19,500 | — | ↗ |
| 2022-06-02 | LEVINE ARNOLD J | Director | A-Award | A | Stock option (right to buy) | 19,500 | 13.56 | 264.4K | 19,500 | — | ↗ |
| 2022-06-02 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 19,500 | 0.00 | — | 19,500 | — | ↗ |
| 2022-06-02 | FLOWERS KIRSTEN | Director | A-Award | A | Stock Option (right to buy) | 19,500 | 13.56 | 264.4K | 19,500 | — | ↗ |
| 2022-06-02 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 19,500 | 13.56 | 264.4K | 19,500 | — | ↗ |
| 2022-05-26 | OrbiMed Genesis GP LLC | Director | S-Sale | D | Common Stock | 26,253 | 15.93 | 418.2K | 87,786 | — | ↗ |
| 2022-05-26 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 26,253 | 15.93 | 418.2K | 87,786 | — | ↗ |
| 2022-04-27 | Mack David Henry | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 33,000 | 0.00 | — | 393,366 | — | ↗ |
| 2022-04-20 | Kung Winston | Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 0.00 | — | 210,034 | — | ↗ |
| 2022-03-31 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 34,500 | 21.17 | 730.4K | 0 | — | ↗ |
| 2022-03-30 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 75,000 | 22.39 | 1.68M | 34,500 | — | ↗ |
| 2022-03-29 | ORBIMED CAPITAL LLC | Director | S-Sale | D | Common Stock | 365,000 | 21.52 | 7.85M | 109,500 | — | ↗ |
| 2022-03-29 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 365,000 | 21.52 | 7.85M | 109,500 | — | ↗ |
| 2022-03-08 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 1.37 | 27.4K | 220,644 | — | ↗ |
| 2022-02-10 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 249,600 | 16.29 | 4.07M | 249,600 | — | ↗ |
| 2022-02-10 | Kung Winston | Officer | A-Award | A | Employee Stock Option (right to buy) | 104,400 | 16.29 | 1.70M | 104,400 | — | ↗ |
| 2022-02-10 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 68,100 | 16.29 | 1.11M | 68,100 | — | ↗ |
| 2022-02-10 | Alland Leila | Officer | A-Award | A | Employee Stock Option (right to buy) | 104,400 | 16.29 | 1.70M | 104,400 | — | ↗ |
| 2022-01-06 | FLOWERS KIRSTEN | Director | M-Exempt | A | Stock Option (right to buy) | 32,677 | 19.06 | 622.8K | 32,677 | — | ↗ |
| 2022-01-05 | FLOWERS KIRSTEN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-30 | Kung Winston | Officer | G-Gift | D | Common Stock | 2,725 | 0.00 | — | 6,600 | — | ↗ |
| 2021-12-15 | Mack David Henry | Officer | M-Exempt | D | Stock Option (right to buy) | 9,000 | 0.53 | 4.8K | 432,574 | — | ↗ |
| 2021-12-09 | Mack David Henry | Director / Officer | G-Gift | A | Common Stock | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-10-06 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 800 | 30.15 | 24.1K | 1,101,283 | — | ↗ |
| 2021-10-04 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 100 | 30.08 | 3.0K | 1,102,083 | — | ↗ |
| 2021-10-01 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 11,541 | 30.10 | 347.4K | 1,102,183 | — | ↗ |
| 2021-09-30 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 2,978 | 30.03 | 89.4K | 1,113,724 | — | ↗ |
| 2021-09-29 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 5,708 | 30.04 | 171.5K | 1,116,702 | — | ↗ |
| 2021-09-27 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,753 | 30.11 | 52.8K | 1,122,410 | — | ↗ |
| 2021-09-22 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 100 | 30.00 | 3.0K | 1,124,163 | — | ↗ |
| 2021-09-22 | LEVINE ARNOLD J | Director | S-Sale | D | Common Stock | 3,500 | 30.00 | 105.0K | 409,842 | — | ↗ |
| 2021-09-17 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 711 | 30.03 | 21.4K | 1,124,263 | — | ↗ |
| 2021-09-13 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 13,272 | 30.20 | 400.8K | 1,124,974 | — | ↗ |
| 2021-09-10 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 38,056 | 30.44 | 1.16M | 1,143,417 | — | ↗ |
| 2021-09-09 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 14,329 | 30.31 | 434.3K | 1,181,473 | — | ↗ |
| 2021-09-09 | Alland Leila | Officer | M-Exempt | A | Common Stock | 100 | 3.90 | 390.00 | 100 | — | ↗ |
| 2021-09-07 | Alland Leila | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,900 | 3.90 | 15.2K | 353,950 | — | ↗ |
| 2021-09-02 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 5,400 | 30.15 | 162.8K | 1,195,802 | — | ↗ |
| 2021-09-01 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 21,986 | 30.38 | 667.9K | 1,201,202 | — | ↗ |
| 2021-08-31 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 19,520 | 30.12 | 587.9K | 1,223,188 | — | ↗ |
| 2021-08-30 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 13,233 | 30.05 | 397.7K | 1,242,708 | — | ↗ |
| 2021-08-27 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,045 | 31.06 | 32.5K | 1,255,941 | — | ↗ |
| 2021-08-26 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 6,091 | 31.13 | 189.6K | 1,280,383 | — | ↗ |
| 2021-08-25 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 13,526 | 31.01 | 419.4K | 1,585,953 | — | ↗ |
| 2021-08-24 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 14,490 | 31.08 | 450.3K | 1,599,479 | — | ↗ |
| 2021-08-23 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 700 | 31.06 | 21.7K | 1,613,969 | — | ↗ |
| 2021-08-23 | LEVINE ARNOLD J | Director | S-Sale | D | Common Stock | 3,500 | 29.50 | 103.3K | 413,342 | — | ↗ |
| 2021-08-19 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 3,800 | 30.97 | 117.7K | 1,637,807 | — | ↗ |
| 2021-08-19 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 5,500 | 0.53 | 2.9K | 441,574 | — | ↗ |
| 2021-08-19 | Kung Winston | Officer | M-Exempt | A | Common Stock | 5,000 | 3.22 | 16.1K | 6,600 | — | ↗ |
| 2021-08-18 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 13,196 | 33.84 | 446.6K | 1,643,844 | — | ↗ |
| 2021-08-17 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 15,746 | 33.93 | 534.3K | 1,668,471 | — | ↗ |
| 2021-08-17 | Jalota Deepika | Officer | M-Exempt | D | Stock option (right to buy) | 2,896 | 3.53 | 10.2K | 87,320 | — | ↗ |
| 2021-08-16 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 2,599 | 34.54 | 89.8K | 1,699,493 | — | ↗ |
| 2021-08-13 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,500 | 34.66 | 52.0K | 1,721,676 | — | ↗ |
| 2021-08-12 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 11,565 | 34.35 | 397.3K | 1,750,933 | — | ↗ |
| 2021-08-11 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 34,439 | 34.04 | 1.17M | 1,762,498 | — | ↗ |
| 2021-08-10 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 17,905 | 34.76 | 622.4K | 1,799,537 | — | ↗ |
| 2021-08-09 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 300 | 36.64 | 11.0K | 1,817,442 | — | ↗ |
| 2021-08-09 | Alland Leila | Officer | S-Sale | D | Common Stock | 224 | 36.69 | 8.2K | 0 | — | ↗ |
| 2021-08-06 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 19,700 | 36.61 | 721.2K | 1,839,824 | — | ↗ |
| 2021-08-05 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 26,871 | 36.38 | 977.6K | 1,868,264 | — | ↗ |
| 2021-08-04 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,760 | 34.21 | 60.2K | 1,946,235 | — | ↗ |
| 2021-08-03 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 100 | 34.74 | 3.5K | 1,947,995 | — | ↗ |
| 2021-08-03 | Kung Winston | Officer | M-Exempt | D | Stock Option (right to buy) | 4,500 | 3.22 | 14.5K | 219,034 | — | ↗ |
| 2021-08-02 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 13,031 | 34.74 | 452.7K | 1,978,240 | — | ↗ |
| 2021-07-29 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 2,300 | 35.73 | 82.2K | 1,991,271 | — | ↗ |
| 2021-07-28 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 8,724 | 35.76 | 312.0K | 1,993,571 | — | ↗ |
| 2021-07-27 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 535 | 35.61 | 19.1K | 2,002,295 | — | ↗ |
| 2021-07-26 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 4,839 | 35.73 | 172.9K | 2,002,830 | — | ↗ |
| 2021-07-23 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 11,988 | 36.00 | 431.6K | 2,007,669 | — | ↗ |
| 2021-07-22 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 200 | 35.61 | 7.1K | 2,019,657 | — | ↗ |
| 2021-07-21 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 18,672 | 35.82 | 668.8K | 2,019,857 | — | ↗ |
| 2021-07-21 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 26,767 | 0.53 | 14.2K | 447,074 | — | ↗ |
| 2021-07-20 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 1,029 | 0.53 | 545.37 | 473,841 | — | ↗ |
| 2021-07-20 | LEVINE ARNOLD J | Director | S-Sale | D | Common Stock | 3,500 | 35.12 | 122.9K | 416,842 | — | ↗ |
| 2021-07-13 | INTERWEST PARTNERS X LP | 10% Owner | J-Other | D | Common Stock | 500,000 | 0.00 | — | 4,469,911 | — | ↗ |
| 2021-07-08 | Kung Winston | Officer | M-Exempt | A | Common Stock | 4,500 | 3.22 | 14.5K | 6,100 | — | ↗ |
| 2021-07-07 | Alland Leila | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 4,000 | 3.90 | 15.6K | 361,850 | — | ↗ |
| 2021-06-28 | Mack David Henry | Director / Officer | M-Exempt | A | Common Stock | 204 | 0.53 | 108.12 | 12,674 | — | ↗ |
| 2021-06-21 | LEVINE ARNOLD J | Director | S-Sale | D | Common Stock | 3,389 | 33.22 | 112.6K | 420,453 | — | ↗ |
| 2021-06-14 | Euclidean Capital LLC | Director | S-Sale | D | Common Stock | 1,260 | 34.11 | 43.0K | 127,099 | — | ↗ |
| 2021-06-11 | Euclidean Capital LLC | Director | S-Sale | D | Common Stock | 3,533 | 33.80 | 119.4K | 728,140 | — | ↗ |
| 2021-06-10 | Euclidean Capital LLC | 10% Owner | S-Sale | D | Common Stock | 3,317 | 32.68 | 108.4K | 731,673 | — | ↗ |
| 2021-06-09 | Euclidean Capital LLC | 10% Owner | S-Sale | D | Common Stock | 6,372 | 33.64 | 214.4K | 734,990 | — | ↗ |
| 2021-06-08 | Euclidean Capital LLC | 10% Owner | S-Sale | D | Common Stock | 17,664 | 33.38 | 589.6K | 2,567,072 | — | ↗ |
| 2021-06-07 | Euclidean Capital LLC | 10% Owner | S-Sale | D | Common Stock | 1,019 | 33.62 | 34.3K | 131,582 | — | ↗ |
| 2021-06-07 | Alland Leila | Officer | S-Sale | D | Common Stock | 1,367 | 34.00 | 46.5K | 0 | — | ↗ |
| 2021-06-04 | Kung Winston | Officer | M-Exempt | A | Common Stock | 4,500 | 3.22 | 14.5K | 6,100 | — | ↗ |
| 2021-06-02 | Stelzer Laurie | Director | A-Award | D | Stock Option | 16,333 | 32.29 | 527.4K | 16,333 | — | ↗ |
| 2021-06-02 | LEVINE ARNOLD J | Director | A-Award | A | Stock option (right to buy) | 16,333 | 32.29 | 527.4K | 16,333 | — | ↗ |
| 2021-06-02 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 16,333 | 32.29 | 527.4K | 16,333 | — | ↗ |
| 2021-06-02 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 16,333 | 32.29 | 527.4K | 16,333 | — | ↗ |
| 2021-06-01 | Heyman Richard A. | Director | M-Exempt | D | Stock Option (right to buy) | 1,950 | 2.95 | 5.8K | 15,901 | — | ↗ |
| 2021-05-28 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 5,100 | 35.80 | 182.6K | 2,038,529 | — | ↗ |
| 2021-05-26 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 7,487 | 35.66 | 267.0K | 2,043,629 | — | ↗ |
| 2021-05-25 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 8,518 | 35.91 | 305.9K | 2,051,116 | — | ↗ |
| 2021-05-24 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 22,095 | 36.03 | 796.1K | 2,059,634 | — | ↗ |
| 2021-05-21 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 19,774 | 35.84 | 708.7K | 2,081,729 | — | ↗ |
| 2021-05-21 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 6,207 | 0.53 | 3.3K | 485,074 | — | ↗ |
| 2021-05-20 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 2,911 | 35.65 | 103.8K | 2,101,503 | — | ↗ |
| 2021-05-20 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 7,793 | 0.53 | 4.1K | 492,867 | — | ↗ |
| 2021-05-20 | LEVINE ARNOLD J | Director | S-Sale | D | Common Stock | 2,961 | 34.68 | 102.7K | 423,842 | — | ↗ |
| 2021-05-12 | Mack David Henry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 134,584 | 28.33 | 3.81M | 134,584 | — | ↗ |
| 2021-05-12 | LEVINE ARNOLD J | Director | A-Award | A | Stock Option (right to buy) | 5,781 | 28.33 | 163.8K | 5,781 | — | ↗ |
| 2021-05-12 | Kung Winston | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,337 | 28.33 | 1.43M | 50,337 | — | ↗ |
| 2021-05-12 | Jalota Deepika | Officer | A-Award | A | Employee Stock Option (right to buy) | 22,674 | 28.33 | 642.4K | 22,674 | — | ↗ |
| 2021-05-12 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 5,781 | 28.33 | 163.8K | 5,781 | — | ↗ |
| 2021-05-12 | Alland Leila | Officer | A-Award | A | Employee Stock Option (right to buy) | 36,279 | 28.33 | 1.03M | 36,279 | — | ↗ |
| 2021-05-10 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,787 | 35.67 | 63.7K | 2,104,414 | — | ↗ |
| 2021-05-10 | INTERWEST PARTNERS X LP | 10% Owner | J-Other | A | Common Stock | 1,135 | 0.00 | — | 3,404 | — | ↗ |
| 2021-05-07 | Alland Leila | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 4,000 | 3.90 | 15.6K | 369,850 | — | ↗ |
| 2021-05-05 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 600 | 35.64 | 21.4K | 2,106,201 | — | ↗ |
| 2021-05-03 | Kung Winston | Officer | M-Exempt | D | Stock Option (right to buy) | 4,500 | 3.22 | 14.5K | 232,534 | — | ↗ |
| 2021-04-28 | Euclidean Capital LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 494,407 | — | ↗ |
| 2021-04-12 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 100 | 33.11 | 3.3K | 2,106,801 | — | ↗ |
| 2021-04-09 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 5,905 | 33.75 | 199.3K | 2,130,562 | — | ↗ |
| 2021-04-08 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 12,621 | 33.82 | 426.8K | 2,157,168 | — | ↗ |
| 2021-04-07 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 100 | 34.50 | 3.5K | 2,169,789 | — | ↗ |
| 2021-04-07 | Alland Leila | Officer | S-Sale | D | Common Stock | 3,972 | 33.86 | 134.5K | 28 | — | ↗ |
| 2021-04-06 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 67,086 | 34.67 | 2.33M | 2,194,246 | — | ↗ |
| 2021-04-05 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 18,990 | 33.46 | 635.4K | 2,302,106 | — | ↗ |
| 2021-04-05 | BAUM CHARLES M | Director | A-Award | A | Stock Option (right to buy) | 32,677 | 34.11 | 1.11M | 32,677 | — | ↗ |
| 2021-04-01 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 12,435 | 32.94 | 409.6K | 2,321,096 | — | ↗ |
| 2021-04-01 | BAUM CHARLES M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-31 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 1,600 | 31.19 | 49.9K | 2,365,557 | — | ↗ |
| 2021-03-30 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 19,207 | 30.82 | 592.0K | 2,370,433 | — | ↗ |
| 2021-03-29 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 764 | 33.16 | 25.3K | 2,389,640 | — | ↗ |
| 2021-03-26 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 35,268 | 33.44 | 1.18M | 2,391,814 | — | ↗ |
| 2021-03-25 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 3,787 | 34.17 | 129.4K | 2,428,282 | — | ↗ |
| 2021-03-24 | Schroeder Thilo | Director | S-Sale | D | Common Stock | 10,100 | 39.00 | 393.9K | 2,493,409 | — | ↗ |
| 2021-03-24 | INTERWEST PARTNERS X LP | 10% Owner | J-Other | A | Common Stock | 2,269 | 0.00 | — | 2,269 | — | ↗ |
| 2021-03-09 | Mack David Henry | Director / Officer | G-Gift | A | Common Stock | 40,000 | 0.00 | — | 80,000 | — | ↗ |
| 2020-12-08 | Kung Winston | Officer | M-Exempt | A | Common Stock | 1,600 | 3.22 | 5.2K | 1,600 | — | ↗ |
| 2020-11-18 | Mack David Henry | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 2,470 | 0.53 | 1.3K | 492,867 | — | ↗ |
| 2020-11-11 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 45,332 | 4.22 | 191.3K | 45,332 | — | ↗ |
| 2020-09-29 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | — | C-Conversion | D | Series D Preferred Stock | 760,267 | 0.00 | — | 0 | — | ↗ |
| 2020-09-29 | Thompson Peter A. | Director / 10% Owner | C-Conversion | D | Series B Preferred Stock | 1,076,891 | 0.00 | — | 0 | — | ↗ |
| 2020-09-29 | Schroeder Thilo | Director / 10% Owner | C-Conversion | A | Common Stock | 760,267 | 0.00 | — | 2,528,290 | — | ↗ |
| 2020-09-29 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | C-Conversion | D | Series D Preferred Stock | 760,265 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
53.33M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 628.5K | — | — | 752.3K | 284.4K | — | 1.67M | 45.18% | ↗ |
| 2 | 2025 | Deepika Jalota, Pharm.D. Chief Development Officer | 478.4K | — | — | 282.1K | 174.6K | — | 935.2K | 30.17% | ↗ |
| 3 | 2025 | Robert Ticktin General Counsel & Chief Operating Officer | 450.0K | — | — | 249.2K | 162.0K | — | 861.2K | 28.94% | ↗ |
| 4 | 2024 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 607.2K | — | 295.0K | 3.52M | 335.9K | — | 4.76M | 80.19% | ↗ |
| 5 | 2024 | Deepika Jalota, Pharm.D. Chief Development Officer | 442.5K | — | 172.0K | 1.12M | 195.8K | — | 1.93M | 66.91% | ↗ |
| 6 | 2024 | Michael Carulli Chief Financial Officer | 370.0K | — | 148.0K | 698.7K | 162.8K | — | 1.38M | 61.38% | ↗ |
| 7 | 2023 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 586.1K | — | — | 1.33M | 295.0K | — | 2.21M | 60.13% | ↗ |
| 8 | 2023 | Winston Kung Former Chief Operating Officer and Chief Financial Officer | 475.3K | — | — | 604.0K | 181.0K | — | 1.26M | 47.92% | ↗ |
| 9 | 2023 | Deepika Jalota, Pharm.D. Chief Development Officer | 421.9K | — | — | 503.3K | 172.0K | — | 1.10M | 45.87% | ↗ |
| 10 | 2022 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 563.8K | — | — | 2.81M | 198.3K | — | 3.58M | 78.69% | ↗ |
| 11 | 2022 | Leila Alland, M.D. Chief Medical Officer | 469.8K | — | 711.0K | 1.18M | 132.2K | — | 2.49M | 75.83% | ↗ |
| 12 | 2022 | Winston Kung Chief Operating Officer and Chief Financial Officer | 461.5K | — | — | 1.18M | 129.8K | — | 1.77M | 66.56% | ↗ |
| 13 | 2022 | Winston Kung Former Chief Operating Officer and Chief Financial Officer | 461.5K | — | — | 1.18M | 129.8K | — | 1.77M | 66.56% | ↗ |
| 14 | 2021 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 545.5K | — | — | 2.65M | 343.8K | — | 3.54M | 74.89% | ↗ |
| 15 | 2021 | Winston Kung Chief Operating Officer and Chief Financial Officer | 448.0K | — | — | 992.1K | 225.1K | — | 1.67M | 59.58% | ↗ |
| 16 | 2021 | Leila Alland, M.D. Chief Medical Officer | 456.1K | — | — | 715.1K | 229.2K | — | 1.40M | 51.06% | ↗ |
| 17 | 2021 | Deepika Jalota, Pharm.D. Chief Regulatory and Quality Officer | 385.0K | — | — | 446.9K | 195.0K | — | 1.03M | 43.52% | ↗ |
| 18 | 2020 | Leila Alland, M.D. Chief Medical Officer | 445.0K | 50.0K | — | 945.0K | 184.7K | — | 1.67M | 56.43% | ↗ |
| 19 | 2020 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 494.6K | — | — | 543.8K | 275.7K | — | 1.31M | 41.38% | ↗ |
| 20 | 2020 | Winston Kung Chief Operating Officer and Chief Financial Officer | 427.5K | — | — | 216.1K | 181.4K | — | 825.4K | 26.19% | ↗ |
| 21 | 2020 | Deepika Jalota, Pharm.D. Chief Regulatory and Quality Officer | 360.2K | — | — | 42.5K | 130.0K | — | 532.7K | 7.98% | ↗ |
| 22 | 2019 | David H. Mack, Ph.D. President, Chief Executive Officer and Director | 461.3K | — | — | — | 166.9K | — | 628.1K | 0.00% | ↗ |
| 23 | 2019 | Winston Kung Chief Operating Officer and Chief Financial Officer | 410.0K | — | — | — | 152.4K | — | 562.4K | 0.00% | ↗ |
| 24 | 2019 | Deepika Jalota, Pharm.D. Chief Regulatory and Quality Officer | 196.9K | — | — | 203.9K | 116.4K | — | 517.1K | 39.43% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David H. Mack | Co-Founder, Chief Executive Officer, President & Director | 912.9K | — |
| Deepika Jalota | Chief Development Officer | 653.1K | — |
| Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary | 612.0K | male |
| Michael Carulli | Chief Financial Officer | 532.8K | male |
| Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board | 140.0K | — |
| Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations | — | male |
| Binh Vu | Senior Vice President of Drug Discovery & CMC | — | — |
| Crystal Zuckerman | Vice President of Human Resources | — | female |
| Laura De Leon | VP & Head of Clinical Development Operations | — | female |
| Marc Fellous | Senior Vice President and Head of Clinical Development & Medical Affairs | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PMVP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
